| Date | Title | Description |
| 04.11.2024 | Cantargia will present at the BioStock Life Science Summit, November 21 | Cantargia will present at the BioStock Life Science Summit, November 21
Mon, Nov 04, 2024 11:00 CET Report this content
The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Göran Forsberg wi... |
| 04.04.2023 | Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023 | Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023
Tue, Apr 04, 2023 12:30 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&... |
| 14.03.2023 | Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer | Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer
Tue, Mar 14, 2023 21:30 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that two abst... |
| 14.03.2023 | Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial | Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial
Tue, Mar 14, 2023 11:40 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that, following posit... |
| 23.02.2023 | Cantargia publishes full year report for 2022 | Cantargia publishes full year report for 2022
Thu, Feb 23, 2023 08:30 CET Report this content
Cantargia AB’s (”Cantargia”) full year report for 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports... |
| 23.02.2023 | Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer | Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer
Thu, Feb 23, 2023 08:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CA... |
| 14.02.2023 | Invitation to presentation of Cantargia’s Year-end report of 2022 on February 23 at 3.00 p.m. CET | Invitation to presentation of Cantargia’s Year-end report of 2022 on February 23 at 3.00 p.m. CET
Tue, Feb 14, 2023 10:00 CET Report this content
Cantargia AB will publish the company’s Year-end report for January-December 2022 on Thursday,... |
| 01.02.2023 | Cantargia announces appointment of Patrik Renblad as Chief Financial Officer | Cantargia announces appointment of Patrik Renblad as Chief Financial Officer
Wed, Feb 01, 2023 15:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based thera... |
| 13.01.2023 | Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application | Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application
Fri, Jan 13, 2023 12:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the Good ... |
| 21.11.2022 | Nomination Committee appointed ahead of 2023 Annual General Meeting | Nomination Committee appointed ahead of 2023 Annual General Meeting
Mon, Nov 21, 2022 11:00 CET Report this content
Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2023 Annual G... |
| 10.11.2022 | Cantargia publishes interim report for third quarter 2022 | Cantargia publishes interim report for third quarter 2022
Thu, Nov 10, 2022 08:30 CET Report this content
Cantargia AB’s (”Cantargia”) interim report for the period January until September 2022 is now available on the company’s web page www... |
| 08.11.2022 | Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022 | Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022
Tue, Nov 08, 2022 16:00 CET Report this content
Strongly supports therapeutic potential in one of CAN10’s lead indic... |
| 07.11.2022 | Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy | Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy
Mon, Nov 07, 2022 14:00 CET Report this content
Data shows nadunolimab dual mechanism potently reduces levels of tumor-promoting molecul... |
| 28.10.2022 | Invitation to presentation of Cantargia’s report for the third quarter of 2022 on November 10 at 3.00 p.m. CET | Invitation to presentation of Cantargia’s report for the third quarter of 2022 on November 10 at 3.00 p.m. CET
Fri, Oct 28, 2022 08:30 CET Report this content
Cantargia AB will publish the company’s report for the third quarter of 2022 on T... |
| 15.09.2022 | Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence | Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence
Thu, Sep 15, 2022 10:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical da... |
| 13.09.2022 | Cantargia presents preclinical data demonstrating unique treatment effects of nadunolimab on pancreatic cancer stromal cells | Cantargia presents preclinical data demonstrating unique treatment effects of nadunolimab on pancreatic cancer stromal cells
Tue, Sep 13, 2022 23:30 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported pr... |
| 31.08.2022 | New number of shares and votes in Cantargia | New number of shares and votes in Cantargia
Wed, Aug 31, 2022 12:30 CET Report this content
The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed rights issue (for further information, see the compa... |
| 30.08.2022 | Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy | Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy
Tue, Aug 30, 2022 08:45 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported publication ... |
| 30.08.2022 | Cantargia publishes half year report | Cantargia publishes half year report
Tue, Aug 30, 2022 08:30 CET Report this content
Cantargia AB’s (”Cantargia”) half year report for the period January until June 2022 is now available on the company’s web page www.cantargia.com/en/invest... |
| 17.08.2022 | Invitation to presentation of Cantargia’s report for the second quarter of 2022 on August 30 at 3.00 p.m. CET | Invitation to presentation of Cantargia’s report for the second quarter of 2022 on August 30 at 3.00 p.m. CET
Wed, Aug 17, 2022 11:30 CET Report this content
Cantargia AB will publish the company’s report for the second quarter for 2022 on ... |
| 25.07.2022 | Cantargia reports new positive preclinical efficacy data for CAN10 supporting development in myocarditis | Cantargia reports new positive preclinical efficacy data for CAN10 supporting development in myocarditis
Mon, Jul 25, 2022 15:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data f... |
| 21.07.2022 | Cantargia receives USPTO Notice of Allowance for composition of matter patent on antibody CAN10 | Cantargia receives USPTO Notice of Allowance for composition of matter patent on antibody CAN10
Thu, Jul 21, 2022 09:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the United States Patent ... |
| 21.07.2022 | Extraordinary general meeting in Cantargia AB (publ) | Extraordinary general meeting in Cantargia AB (publ)
Thu, Jul 21, 2022 11:45 CET Report this content
Cantargia’s extraordinary general meeting on 21 July 2022 resolved in accordance with the following: To, in accordance with the board’s pro... |
| 08.07.2022 | Cantargia appoints Dr. Dominique Tersago as Chief Medical Officer | Cantargia appoints Dr. Dominique Tersago as Chief Medical Officer
Fri, Jul 08, 2022 14:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the strengthening of its management team through the appoint... |
| 04.07.2022 | Cantargia to hold webcast briefing on recently announced rights issue | Cantargia to hold webcast briefing on recently announced rights issue
Mon, Jul 04, 2022 14:00 CET Report this content Cantargia rights issue webcast to take place on July 7, 2022 at 2:00 PM CET/8:00 AM ET Recently presented positive clinica... |
| 21.06.2022 | Notice of extraordinary general meeting in Cantargia AB (publ) | Notice of extraordinary general meeting in Cantargia AB (publ)
Tue, Jun 21, 2022 23:45 CET Report this content
The shareholders of Cantargia AB (publ) are invited to the extraordinary general meeting on Thursday, 21 July 2022. The extraordi... |
| 09.06.2022 | Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer | Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer
Thu, Jun 09, 2022 15:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will... |
| 26.05.2022 | Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor | Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor
Thu, May 26, 2022 23:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) to... |
| 26.05.2022 | Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC | Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC
Thu, May 26, 2022 23:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported updated interim resul... |
| 26.05.2022 | Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer | Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer
Thu, May 26, 2022 23:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported e... |
| 23.05.2022 | Cantargia publishes interim report for first quarter 2022 | Cantargia publishes interim report for first quarter 2022
Mon, May 23, 2022 08:30 CET Report this content
Cantargia AB’s (”Cantargia”) interim report for first quarter 2022 is now available on the company’s web page www.cantargia.com/en/inv... |
| 23.05.2022 | Annual General Meeting in Cantargia AB (publ) | Annual General Meeting in Cantargia AB (publ)
Mon, May 23, 2022 17:30 CET Report this content
Cantargia’s Annual General Meeting on 23 May 2022 resolved in accordance with the following:
That no dividend would be paid. To discharge the boar... |
| 22.05.2022 | Cantargia reports positive preclinical effects in atherosclerosis demonstrating potential of CAN10 in cardiovascular disease | Cantargia reports positive preclinical effects in atherosclerosis demonstrating potential of CAN10 in cardiovascular disease
Sun, May 22, 2022 09:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported ne... |
| 17.05.2022 | Invitation to presentation of Cantargia’s report for the first quarter of 2022 on May 23 at 10.00 a.m. CET | Invitation to presentation of Cantargia’s report for the first quarter of 2022 on May 23 at 10.00 a.m. CET
Tue, May 17, 2022 09:30 CET Report this content
Cantargia AB will publish the company’s report for the first quarter for 2022 on Mond... |
| 29.04.2022 | Cantargia publishes annual report for the financial year 2021 | Cantargia publishes annual report for the financial year 2021
Fri, Apr 29, 2022 13:00 CET Report this content
Cantargia AB's annual report for the financial year 2021 is now available on the company's website (www.cantargia.com) and at the ... |
| 27.04.2022 | Cantargia to present new clinical data on lead IL1RAP antibody nadunolimab over three sessions at ASCO 2022 | Cantargia to present new clinical data on lead IL1RAP antibody nadunolimab over three sessions at ASCO 2022
Wed, Apr 27, 2022 16:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) will present three posters with ne... |
| 22.04.2022 | Notice of annual general meeting in Cantargia AB (publ) | Notice of annual general meeting in Cantargia AB (publ)
Fri, Apr 22, 2022 13:00 CET Report this content
The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Monday, 23 May 2022, at 16.00 CET at Ideon Gateway,... |
| 10.03.2022 | Correction: Cantargia strengthens executive management in preparation for late-stage clinical development | Correction: Cantargia strengthens executive management in preparation for late-stage clinical development
Thu, Mar 10, 2022 15:00 CET Report this content
Adjustment to regulatory in previous press release “Cantargia strengthens executive ma... |
| 10.03.2022 | Cantargia strengthens executive management in preparation for late-stage clinical development | Cantargia strengthens executive management in preparation for late-stage clinical development
Thu, Mar 10, 2022 14:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the strengthening of its medical... |
| 01.03.2022 | Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis | Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis
Tue, Mar 01, 2022 11:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA)... |
| 24.02.2022 | Cantargia publishes full year report for 2021 | Cantargia publishes full year report for 2021
Thu, Feb 24, 2022 08:30 CET Report this content
Cantargia AB’s (”Cantargia”) full year report for 2021 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports... |
| 22.02.2022 | Cantargia reports encouraging new CAN10 toxicology results and schedules phase I trial for 2023 | Cantargia reports encouraging new CAN10 toxicology results and schedules phase I trial for 2023
Tue, Feb 22, 2022 15:00 CET Report this content
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new encouraging results from no... |
| 08.02.2022 | Invitation to presentation of Cantargia’s report for the fourth quarter of 2021 on February 24 at 3.00 p.m. CET | Invitation to presentation of Cantargia’s report for the fourth quarter of 2021 on February 24 at 3.00 p.m. CET
Tue, Feb 08, 2022 13:00 CET Report this content
Cantargia AB will publish the company’s report for the fourth quarter for 2021 o... |
| 04.02.2022 | Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study | Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study
Fri, Feb 04, 2022 09:00 CET Report this content
Cantargia AB today reported that the first patient in the new non-squamous non-... |
| 03.02.2022 | Cantargia reports positive safety data from CIRIFOUR clinical study on nadunolimab and pembrolizumab combination | Cantargia reports positive safety data from CIRIFOUR clinical study on nadunolimab and pembrolizumab combination
Thu, Feb 03, 2022 09:30 CET Report this content
Cantargia AB today reported an interim update on the first part of the phase Ib... |
| 19.01.2022 | Cantargia reports third party appeal against EPO decision in favor of Cantargia patent | Cantargia reports third party appeal against EPO decision in favor of Cantargia patent Wed, Jan 19, 2022 14:30 CET
Cantargia AB today reported that a third party has filed a Notice of Appeal after their previous unsuccessful attempt to chal... |
| 14.01.2022 | Cantargia reports treatment of first triple negative breast cancer patient in TRIFOUR study | Cantargia reports treatment of first triple negative breast cancer patient in TRIFOUR study Fri, Jan 14, 2022 14:00 CET
Cantargia AB today reported treatment of the first triple negative breast cancer (TNBC) patient with nadunolimab and che... |
| 03.01.2022 | Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise[SM] phase 2/3 clinical trial | Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise[SM] phase 2/3 clinical trial Mon, Jan 03, 2022 08:30 CET
Cantargia AB today announced that the Pancreatic Cancer Action Network’s (PanCAN) Precision Pr... |
| 03.01.2022 | Cantargia : Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise phase 2/3 clinical trial | Cantargia AB today announced that the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM phase 2/3 clinical trial, carried out at leading clinical US centers, plans to include nadunolimab in combination with chemotherapy as fir... |
| 29.12.2021 | Cantargia reports updated encouraging survival data from CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer | Cantargia reports updated encouraging survival data from CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer Wed, Dec 29, 2021 14:15 CET
Cantargia AB today announced updated interim results from the CANFOUR phase I/IIa clin... |
| 28.12.2021 | Cantargia announces publication of two scientific articles on nadunolimab | Cantargia announces publication of two scientific articles on nadunolimab Tue, Dec 28, 2021 14:30 CET
Cantargia AB today reported publication of two articles in peer-reviewed scientific journals. The first, published in British Journal of C... |
| 13.12.2021 | Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model | Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model Mon, Dec 13, 2021 13:00 CET
Cantargia AB today reported new preclinical results demonstrating efficacy of the CAN10 antibody in a systemic scleros... |
| 01.12.2021 | Cantargia reports opposition against recently granted European patent | Cantargia reports opposition against recently granted European patent Wed, Dec 01, 2021 16:00 CET
Cantargia AB reported today that oppositions have been filed against one of Cantargia’s European patents, EP3293202. This patent provides a br... |
| 11.11.2021 | Cantargia publishes interim report for third quarter 2021 | Cantargia publishes interim report for third quarter 2021 Thu, Nov 11, 2021 08:30 CET
Cantargia AB’s (”Cantargia”) interim report for the period January until September 2021 is now available on the company’s web page www.cantargia.com/en/in... |
| 08.11.2021 | (R) Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10 | Cantargia AB today provided an update on the progress in the development of a manufacturing process for CAN10 and the clinical trial preparations, with minor adjustments to the timeline. Development of a manufacturing process for CAN10 has ... |
| 08.11.2021 | Invitation to presentation of Cantargia’s report for the third quarter of 2021 on November 11 at 3.00 p.m. CET | Invitation to presentation of Cantargia’s report for the third quarter of 2021 on November 11 at 3.00 p.m. CET Mon, Nov 08, 2021 13:00 CET
Cantargia AB will publish the company’s report for the period July – September 2021 on Thursday, Nove... |
| 08.11.2021 | Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10 | Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10 Mon, Nov 08, 2021 15:45 CET
Cantargia AB today provided an update on the progress in the development of a manufactu... |
| 29.10.2021 | Nomination Committee appointed ahead of 2022 Annual General Meeting | Nomination Committee appointed ahead of 2022 Annual General Meeting Fri, Oct 29, 2021 14:30 CET
Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2022 Annual General Meeting, and ... |
| 22.10.2021 | Cantargia reports treatment of first patient in CESTAFOUR clinical trial | Cantargia reports treatment of first patient in CESTAFOUR clinical trial Fri, Oct 22, 2021 15:30 CET
Cantargia AB today announced that the first patient has started treatment with nadunolimab (CAN04) and chemotherapy in the phase I/II clini... |
| 22.10.2021 | Cantargia : Cantargia reports treatment of first patient in CESTAFOUR clinical trial | Cantargia AB today announced that the first patient has started treatment with nadunolimab (CAN04) and chemotherapy in the phase I/II clinical trial CESTAFOUR. This trial evaluates CAN04 in combination with standard of care chemotherapy in ... |
| 14.10.2021 | Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer | Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer Thu, Oct 14, 2021 08:30 CET
Cantargia AB today announced that the Committee for Orphan Medicinal Products (COMP) at the Europea... |
| 14.10.2021 | Cantargia : Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer | Cantargia AB today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer. The ... |
| 30.09.2021 | Cantargia’s extensive patent protection for IL1RAP-targeting cancer therapy remains in force after concluded opposition | Cantargia’s extensive patent protection for IL1RAP-targeting cancer therapy remains in force after concluded opposition Thu, Sep 30, 2021 11:30 CET
Cantargia AB holds a large number of granted patents related to IL1RAP as a target for antib... |
| 29.09.2021 | Cantargia : Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer | Cantargia AB today announced that the clinical trial application for the phase Ib/II clinical study TRIFOUR has received approval by the regulatory authority and ethics committee in Spain. This study broadens Cantargia's clinical program to... |
| 29.09.2021 | Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer | Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer Wed, Sep 29, 2021 16:30 CET
Cantargia AB today announced that the clinical trial application for the phase Ib/II clinical study TRIFOUR has recei... |
| 22.09.2021 | Cantargia: FDA grants Orphan Drug Designation to nadunolimab for treatment of pancreatic cancer | Cantargia: FDA grants Orphan Drug Designation to nadunolimab for treatment of pancreatic cancer Wed, Sep 22, 2021 16:30 CET
Cantargia AB today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation in t... |
| 16.09.2021 | Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress | Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress Thu, Sep 16, 2021 08:30 CET
Cantargia AB today presented novel interim results in non-small cell lung cancer (NSCLC) patients for nadunolimab (CAN... |
| 13.09.2021 | Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress | Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress Mon, Sep 13, 2021 00:05 CET
Cantargia AB today announced the publication of an abstract disclosing novel ... |
| 10.09.2021 | Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy | Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy Fri, Sep 10, 2021 13:30 CET
Cantargia AB today announced approval to start the phase I/II clinical study CESTAFOUR by... |
| 10.09.2021 | Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study | Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study Fri, Sep 10, 2021 13:00 CET
Cantargia AB today announced that all planned 40 patients with advanced pancreatic cancer (PDAC) ha... |
| 10.09.2021 | Cantargia : Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy | Cantargia AB today announced approval to start the phase I/II clinical study CESTAFOUR by the regulatory authority and ethics committee in France. This study broadens the clinical development for nadunolimab (CAN04) to include biliary tract... |
| 06.09.2021 | Cantargia : Cantargia expands nadunolimab development in non-squamous NSCLC | Cantargia AB today announced the clinical development status and next steps of nadunolimab (CAN04) in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC). As therapies differ between subgroups of NSCLC, future... |
| 06.09.2021 | Cantargia expands nadunolimab development in non-squamous NSCLC | Cantargia expands nadunolimab development in non-squamous NSCLC Mon, Sep 06, 2021 16:45 CET
Cantargia AB today announced the clinical development status and next steps of nadunolimab (CAN04) in combination with platinum-based chemotherapy i... |
| 01.09.2021 | Cantargia strengthens the company management team | Cantargia strengthens the company management team Wed, Sep 01, 2021 09:00 CET
Cantargia AB (publ) (Cantargia) announced today that Nedjad Losic has been employed as VP Biometrics at Cantargia from 1 September 2021. He will be part of the ma... |
| 30.08.2021 | Cantargia reports preclinical data highlighting advantages of nadunolimab mechanism of action | Cantargia reports preclinical data highlighting advantages of nadunolimab mechanism of action Mon, Aug 30, 2021 14:30 CET
Cantargia AB today report new preclinical data on the antibody nadunolimab (CAN04) in combination with the chemotherap... |
| 26.08.2021 | Cantargia reports first patient treated in CAPAFOUR study investigating combination of nadunolimab with FOLFIRINOX in pancreatic cancer | Cantargia reports first patient treated in CAPAFOUR study investigating combination of nadunolimab with FOLFIRINOX in pancreatic cancer Thu, Aug 26, 2021 13:00 CET
Cantargia AB today announced that the first patient has received treatment w... |
| 19.08.2021 | Cantargia : Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm | Cantargia AB today announced that the last patient in the initial treatment arm of the phase Ib clinical study CIRIFOUR has started treatment. A total of 15 patients have so far been recruited to this study, which evaluates nadunolimab (CAN... |
| 19.08.2021 | Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm | Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm Thu, Aug 19, 2021 11:30 CET
Cantargia AB today announced that the last patient in the initial treatment arm of the phase Ib cli... |
| 19.08.2021 | Cantargia publishes half year report | Cantargia publishes half year report Thu, Aug 19, 2021 08:30 CET
Cantargia AB’s (”Cantargia”) half year report for the period January until June 2021 is now available on the company’s web page www.cantargia.com/en/investors/financial-report... |
| 10.08.2021 | Invitation to presentation of Cantargia’s report for the second quarter of 2021 on August 19 at 3.00 p.m. CET | Invitation to presentation of Cantargia’s report for the second quarter of 2021 on August 19 at 3.00 p.m. CET Tue, Aug 10, 2021 08:30 CET
Cantargia AB will publish the company’s report for the period April – June 2021 on Thursday, August 19... |
| 08.06.2021 | Cantargia receives regulatory approval to start clinical trial investigating nadunolimab and FOLFIRINOX in pancreatic cancer | Cantargia receives regulatory approval to start clinical trial investigating nadunolimab and FOLFIRINOX in pancreatic cancer Tue, Jun 08, 2021 10:00 CET
Cantargia AB today announce that the clinical trial application to investigate the anti... |
| 08.06.2021 | CANTARGIA AB (PUBL)
Cantargia : Cantargia receives regulatory approval to start clinical trial investigating nadunolimab and FOLFIRINOX in pancreatic cancer | Cantargia AB today announce that the clinical trial application to investigate the antibody nadunolimab (CAN04) in combination with the FOLFIRINOX chemotherapy regimen for first line treatment of metastatic pancreatic cancer (PDAC), has bee... |
| 26.05.2021 | Cantargia publishes interim report for first quarter 2021 | Cantargia publishes interim report for first quarter 2021 Wed, May 26, 2021 08:30 CET
Cantargia AB’s (”Cantargia”) interim report for first quarter 2021 is now available on the company’s web page www.cantargia.com/en/investors/financial-rep... |
| 26.05.2021 | Annual General Meeting in Cantargia AB (publ) | Annual General Meeting in Cantargia AB (publ) Wed, May 26, 2021 17:30 CET
Cantargia’s Annual General Meeting on 26 May 2021 resolved in accordance with the following: That no dividend would be paid To discharge the board members and the man... |
| 19.05.2021 | Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy | Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy Wed, May 19, 2021 23:00 CET
Cantargia AB today announced positive results from the ongoing CANFOUR trial investig... |
| 27.05.2020 | CANTARGIA AB (PUBL)
Cantargia publ : publishes interim report for first quarter 2020 | Cantargia AB's ("Cantargia") interim report for first quarter 2020 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant events in the first quarter
· Cantargia advanced its devel... |
| 27.05.2020 | CANTARGIA AB (PUBL)
Cantargia publ : Cantargia publishes interim report for first quarter 2020 | Cantargia AB's ('Cantargia') interim report for first quarter 2020 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant events in the first quarter
Cantargia advanced its development of CA... |
| 05.07.2013 | Cantargia Raises SEK7M | Cantargia, a Lund, Sweden-based biopharmaceutical company developing therapeutics for the treatment of leukemia, raised SEK7m.
Backers included Sunstone Capital, which invested €500k from its Early Engagement Program (EEP) and LUBio, which ... |
